Merck jumps as lab demand lifts 2026 outlook
View all comments(0)
Germany's Merck MRCG.DE is up 4.4% in early Frankfurt trade after it raised its full-year guidance on stronger demand for its lab supplies and delayed competition for its Mavenclad multiple sclerosis drug
The science and healthcare firm also reported higher-than-expected Q1 EBITDA of 1.53 billion euros, beating average analyst expectations of 1.46 billion euros
"Given the strong set of results and FY’26 Guidance upgrade... we expect the shares to outperform by 2-3% today," JPMorgan says
The stock is at the top of German blue-chip index DAX .GDAXI in early Frankfurt trade
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

SK Hynix Surges 15% to New High: HBM Shortage Until 2028, How Much Longer Can AI Memory King Rise?

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.